[HTML] frontiersin.org

[HTML][HTML] TP53 co-mutations in advanced EGFR-mutated non–small cell lung cancer: Prognosis and therapeutic strategy for cancer therapy

S Liu, J Yu, H Zhang, J Liu - Frontiers in oncology, 2022 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
被引用次数：23 相关文章

TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy.

S Liu, J Yu, H Zhang, J Liu - Frontiers in Oncology, 2022 - europepmc.org
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
[HTML] nih.gov

[HTML][HTML] TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy

S Liu, J Yu, H Zhang, J Liu - Frontiers in Oncology, 2022 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …

TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy

S Liu, J Yu, H Zhang, J Liu - Frontiers in oncology, 2022 - pubmed.ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …